Clinical trialNCT07723651Not, yet, recruitingPhase 2Interventional

[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

SponsorWashington University School of MedicineEnrollment75Metastatic Prostate CancerProstate Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This multicenter center, open-label, baseline-controlled diagnostic imaging study designed to assess the use of Fluorthanatrace-Positron Emission tomography (FTT-PET) as a PARP inhibitor (PARPi) therapy predictive imaging biomarker and the use of EnhanceAR-Seq (ctDNA) in predicting response to therapy and to identify genomic alterations associated with resistance. Furthermore, to correlate changes in ctDNA and imaging (FTT-PET and standard of care imaging) to understand the dynamics of tumor response.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Farrokh Dehdashti, MD
Washington University School of Medicine
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Washington University School of Medicine
St Louis, Missouri, United States
Buck Rogers, PhDChristopher A Maher, PhDCody Weimholt, MDKooresh I Shoghi, PhDMelissa A Reimers, MDRichard Laforest, PhDYu Tao, MD
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Nei Taunk, MD
University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Franklin Wong, MDLilie Lin, MDPatrick G Pilie, MD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

1-phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6-one

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Sept 2026
Primary completion: 31 Mar 2032
Completion: 31 Mar 2032
Last update posted: 23 Jul 2026
Registered enrollment: 75
Registry id: NCT07723651

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.